K
Kristian Reich
Researcher at University of Hamburg
Publications - 204
Citations - 9031
Kristian Reich is an academic researcher from University of Hamburg. The author has contributed to research in topics: Psoriasis & Psoriasis Area and Severity Index. The author has an hindex of 43, co-authored 203 publications receiving 5894 citations.
Papers
More filters
Journal ArticleDOI
Epidemiology and comorbidity of psoriasis in children
Matthias Augustin,Gerd Glaeske,Marc Alexander Radtke,Enno Christophers,Kristian Reich,Ines Schäfer +5 more
TL;DR: This study focuses on the epidemiology of childhood psoriasis, which is a common disease affecting all age groups and has little literature on its epidemiology.
Journal ArticleDOI
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†
Kim A. Papp,Kristian Reich,Carle Paul,Andrew Blauvelt,W. Baran,Chantal Bolduc,Darryl Toth,Richard G. Langley,J. Cather,Alice B. Gottlieb,Diamant Thaçi,James G. Krueger,Chris B. Russell,Cassandra E Milmont,Joanne Li,Paul Klekotka,Gregory Kricorian,Ajay Nirula +17 more
TL;DR: The interleukin‐17 cytokine family plays a central role in psoriasis pathogenesis and is associated with atypical immune responses and central nervous system disorders.
Journal ArticleDOI
Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis
TL;DR: This poster discusses how best to select a dermatologist for the initial diagnosis of psoriatic arthritis based on the individual patient's history, symptoms, and once-and-a-half-year-old to six-month-old twins.
Journal ArticleDOI
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)
M S de Bruin-Weller,Diamant Thaçi,Catherine H. Smith,Kristian Reich,Michael J. Cork,Allen Radin,Q. Zhang,Bolanle Akinlade,Abhijit Gadkari,Laurent Eckert,Thomas Hultsch,Zhen Chen,Gianluca Pirozzi,Neil M.H. Graham,Brad Shumel +14 more
TL;DR: D Dupilumab, a fully human anti‐interleukin 4 receptor‐alpha monoclonal antibody, inhibits signaling of IL‐4 and IL‐13, key drivers of Type 2/Th2‐mediated inflammation, and is approved in the U.S.A. and the European Union for the treatment of inadequately‐controlled moderate‐to‐severe atopic dermatitis in adults.
Journal ArticleDOI
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Eric L. Simpson,Jean-Philippe Lacour,Lynda Spelman,R. Galimberti,Lawrence F. Eichenfield,Robert Bissonnette,Brett A. King,Jacob P. Thyssen,Jonathan I. Silverberg,T. Bieber,Kenji Kabashima,Y. Tsunemi,Antonio Costanzo,Emma Guttman-Yassky,Lisa A. Beck,Jonathan Janes,Amy M. DeLozier,Margaret Gamalo,Dennis Brinker,Tracy Cardillo,Fabio P. Nunes,Amy S. Paller,A. Wollenberg,Kristian Reich +23 more
TL;DR: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids.